ライフサイエンスコーパス: target organ

1 sequestration) or harmful (toxin delivery to target organs).

2 y directly applying it to specimens from the target organ.

3 contribute to the pathogenic damaging of the target organ.

4 to this functional state upon infiltrating a target organ.

5 g of the laparoscope and registration of the target organ.

6 zed by ectopic lymphoid follicles within the target organ.

7 eactive T cells in the intestine, a key GVHD target organ.

8 in an ongoing adaptive immune response in a target organ.

9 by many autoimmune TCRs are abundant in the target organ.

10 f beryllium-responsive CD4(+) T cells in the target organ.

11 le sclerosis in which T(EM) are found in the target organ.

12 l phenotypes, support the kidney as the main target organ.

13 tion responding to hemodynamic injury in the target organ.

14 essly integrate and restore functions of the target organ.

15 be eliminated or diverted from reaching the target organ.

16 volved in the induction of severe disease in target organs.

17 and maintenance of CD4+ effector T cells in target organs.

18 anded in vivo and invaded lymphatic and GVHD target organs.

19 e variants act in sympathetically innervated target organs.

20 n, which in turn cause insulin resistance in target organs.

21 80(+) cells ("F4/80(+) cells") in metastatic target organs.

22 g from the CNS to the periphery to reach the target organs.

23 tor T cells, and lymphocytic infiltration of target organs.

24 ntially play a role in inflamed hypoxic GvHD target organs.

25 ssential for sympathetic axon innervation of target organs.

26 lammatory infiltrate into the peritoneum and target organs.

27 3 ligand-mediated lymphocyte infiltration of target organs.

28 , cytokine production, and migration to GVHD target organs.

29 nd gastrointestinal tract as primary CBLB502 target organs.

30 -effector cells (Teffs) that migrate to GVHD target organs.

31 whether putative dysfunction exists only in target organs.

32 butes to the trafficking of WT Tconv to GVHD target organs.

33 ability to be activated by self-antigens in target organs.

34 ated by altered trafficking of Tconv to GVHD target organs.

35 nd glucuronidated forms that are exported to target organs.

36 for both Tregs and Tconv to migrate to GVHD target organs.

37 induced an increased metastatic activity to target organs.

38 in extravasation and homing of leukocytes to target organs.

39 ty because of activated T cells infiltrating target organs.

40 that favor successful colonization of distal target organs.

41 ct, with the liver one of the most important target organs.

42 opulation, and are present in all major GVHD target organs.

43 pathways that are co-expressed in IMIDs and target organs.

44 nucleases and enable distribution to desired target organs.

45 pread from the inoculation site to secondary target organs.

46 MX001 acts by reducing Ad replication in key target organs.

47 within aggregated lipid rafts guides them to target organs.

48 es to host tissues and by direct toxicity to target organs.

49 r RBP and mediates vitamin A uptake in these target organs.

50 early effector migration to GVHD parenchymal target organs.

51 ffect needed to control virus infectivity in target organs.

52 uencing whole-body metabolism via effects on target organs.

53 he colonization and growth of tumor cells in target organs.

54 ns, thereby reducing fungal dissemination to target organs.

55 ite the presence of intact hair cells in the target organs.

56 ons during metastasis of cancer to different target organs.

57 cle structure affects biodistribution to off-target organs.

58 by activation of diverse immune cells in the target organs.

59 ppressor cells (MDSCs) were enriched in GVHD target organs.

60 orable microenvironment in the stroma of the target organs.

61 undergo metastatic reactivation in multiple target organs.

62 in the body to attain therapeutic effects at target organs.

63 ic catheters and confer specific delivery to target organs.

64 minate to cause systemic infection and reach target organs.

65 ever, remain unclear and differ depending on target organs.

66 invaded locally, intravasated and lodged in target organs.

67 cer cells that is invasive and can spread to target organs.

68 e, whereas WT virus is readily detectable in target organs 30 d after infection, some variants fail t

69 itrite bioactivation by myoglobin within the target organ abrogated the cardioprotection by rIPC.

70 master at exploiting leukocytes to reach its target organs, accordingly evading the host immunity.

71 The major target organs affected are skin, lungs, and liver.

72 s highly enriched for genes expressed in the target organs affected by chronic GVHD.

73 with an improved control of viral titers in target organs after the development of the specific immu

74 mics of RSV-specific T-cell responses in the target organ, allowing the precise investigation of Trm

75 proliferation of T cells in situ within the target organ, an effect that would be expected to restra

76 echanisms of how these cells recognize their target organ and induce sustained inflammation are incom

77 ut not necessarily all, CD8(+) Teff into the target organ and suggest a novel approach to achieve tra

78 e, suggesting that the genetic origin of the target organ and/or its innate immune cells is critical

79 s, and antibodies promote dysfunction of the target organs and cause damage.

80 kines, followed by decreased inflammation in target organs and increment in parasite burden.

81 e of the most-reduced transcripts in several target organs and is hypothesized to have a causal role

82 its diverse metabolic functions in multiple target organs and its ability to act as an autocrine, pa

83 l peptides studied, with saturable uptake in target organs and low uptake by nontarget tissues other

84 kely elicits systemic molecular responses in target organs and may contribute to whole-plant stress t

85 implicated the kidney and liver as the main target organs and prioritized potentially causal genes a

86 r, these cells migrate to and expand in GVHD target organs and secondary lymphoid tissues.

87 to rapidly innervate and arborize into final target organs and then slow but not halt their growth to

88 appears that in the absence of Nmnat2, major target organs and tissues (e.g., muscle) are not functio

89 bility of T-bet(-/-) T cells to migrate into target organs and to produce Th1-related cytokines.

90 onsiderable research into adjuvant therapies targeting organ and tissue dysfunction, none have shown

91 sis, tissue-toxic neutrophil accumulation in target organs, and GM-CSF prophylactic or therapeutic bl

92 e majority of sporozoites do not reach their target organs, and in the mammalian host, they initiate

93 metabolic changes, the immune landscapes of target organs, and variation in epithelial-mesenchymal t

94 In the metastasis-targeted organs, angiogenesis is essential for the progr

95 he cell-type diversity and function of their target organ are valuable for basic and translational re

96 the delivery of the therapeutic cells to the target organs are getting more and more into the focus o

97 come dormant and how and why tumors recur in target organs are not well understood.

98 switch of homeostasis rather than a passive target organ as hitherto conceived.

99 ow that a similar process takes place in the target organ, as both alpha and beta cells within pancre

100 t tissues or organs before the injury of the target organ, attempts to invoke adaptive responses that

101 inhibited lymphoid infiltrates in different target organs based on the Y RNA and TLR status of the m

102 nic functions of CD4(+) T cells within their target organ but not in lymphoid tissues during EAE.

103 at strategies aimed not at target tissues or target organs but rather at restoring the quality and qu

104 infiltration into graft-versus-host reaction target organs, but decreased the functional activity of

105 Autoreactive T cells infiltrating the target organ can possess a broad TCR affinity range.

106 contributions to good health that all 36 VDR target organs can provide.

107 etic ganglia (TSG) and transaxonal spread to target organs cause human visceral disease.

108 ether biomarkers can identify silent cardiac target organ damage (cTOD) in a primary prevention popul

109 ss of circadian BP change has been linked to target organ damage and accelerated kidney function loss

110 of this study was to determine hypertensive target organ damage and adverse cardiovascular outcomes

111 Patients with PA more frequently displayed target organ damage and cardiovascular events compared w

112 pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease

113 vation of a cellular immune response, or off-target organ damage by BNP116.I-1c gene therapy in pigs.

114 orenal adverse remodeling, contribute to the target organ damage found in hypertension, heart failure

115 T(1) receptors may have divergent effects on target organ damage in hypertension.

116 risk score was significantly associated with target organ damage in multiple tissues but with minor e

117 ely discrepant effects on blood pressure and target organ damage in this disorder.

118 blood pressure, presence of risk factors and target organ damage subjects were divided into 4 groups:

119 toring, is associated with increased risk of target organ damage, cardiovascular disease, and mortali

120 ture of blood pressure and assess effects on target organ damage, we analyzed 128,272 SNPs from targe

121 l activation and differentiation, as well as target organ damage.

122 recruitment as a key step in development of target organ damage.

123 xcretion might be involved in cardiovascular target organ damage.

124 one and consequent cardiac, renal, and brain target organ damage.

125 m cytokine production in vivo, and prevented target organ damage.

126 ssion and may play a role in smoking-induced target organ damage.

127 ediators of smoking-induced inflammation and target organ damage.

128 xtensive transcriptomic changes that lead to target-organ damage and smoking-related diseases.

129 Subtle target-organ damage such as left-ventricular hypertrophy

130 ient screening test for hypertension-related target-organ damage.

131 of T helper 1 and T helper 17 cells in GVHD target organs, demonstrating that blockade of IL-6 signa

132 These findings suggest a target organ-derived neurotrophin suppresses development

133 ong recognized that only a limited subset of target organs develop clinically overt metastases.

134 een drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascu

135 re they multiply and often spread to various target organs: disseminated skin sites, the central nerv

136 t role in regulating TSP-1 production in the target organ during acute inflammation.

137 a unique opportunity to deliver siRNA to the target organ during ex situ preservation.

138 The kidney is the target organ during infection and whose control is large

139 tivity of immune pathology within individual target organs during GVHD.

140 their concomitant roles at protein levels in target organs during human allergic disease have not bee

141 tension, and AKI is a frequent form of acute target organ dysfunction, particularly in those with bas

142 e microvasculature is necessary to reach its target organs (e.g., adipose and muscle tissues) and is

143 of action, block of related channels in non-target organs, e.g. the heart, can result in major and p

144 eveal that Cdk5 activity is increased in key target organs early after allo-HCT.

145 d NK cells led to far greater viral loads in target organs early after infection compared with nondep

146 ficant metabolic and cytoskeleton changes in target organ ECs in gene array and proteomic analyses.

147 inephrine contributed to neuronal control of target organ effector cells.

148 and the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases.

149 trafficking of IFNgammaR(-/-) Tconv to GVHD target organs, especially the gastrointestinal (GI) trac

150 cells effectively eliminates B cells in the target organ even though thyroid B cells have decreased

151 e effects of AT1 receptor stimulation in the target organ, exogenous administration of AT2 receptor a

152 perior potency and very good oral as well as target organ exposure in rats.

153 y germinal center reactions and resulting in target organ fibrosis.

154 The lungs are the target organ for COVID-19; patients develop acute lung i

155 abolic process, which makes it an attractive target organ for gene therapy.

156 The kidney is a target organ for human cytomegalovirus (hCMV) in such pa

157 previously showed that the brain was a major target organ for infection in mice that are transgenic f

158 ducing skin as a nonconventional, peripheral target organ for regulation by TSH.

159 The liver serves as a target organ for several important pathogens, including

160 The eye is an excellent target organ for such cell-based therapeutics due to its

161 the thymus, gut, brain and other tissues as target organs for consideration in developing a new unde

162 nor cells significantly reduced systemic and target organ GVHD severity, and CCR1 expression on both

163 tically reduced the severity of systemic and target organ GVHD.

164 nts and their pharmacological sensitivity in target organs has proved difficult.

165 e aggressive goals (<130 mm Hg), we observed target organ heterogeneity in that the risk of stroke co

166 case of cortisol) circulating levels of the target-organ hormones.

167 ge in the acute and chronic GVHD overlapping target organs (i.e., skin and lung); they also markedly

168 I and phosphorylated SMAD3) increases in the target organs, i.e., kidneys, of these mice as they age

169 is an important but previously unrecognized target organ in SLE with neutrophil-mediated IFN activat

170 ex steroid concentrations and bioactivity on target organs in mice expressing a human SHBG transgene.

171 y of interactions between adipose tissue and target organs in obesity and the resulting clinical impl

172 lar to WT T cells and accumulated in SLO and target organs in similar numbers as WT T cells.

173 s and the efficiency of replication in major target organs in subcutaneously inoculated ducks.

174 as a vehicle to reach the endothelium of the target organs in the absence or presence of immune surve

175 ntuitive webtool allowing a user to identify target organs in the human body where a substance is est

176 ed virus (AAV), thereby allowing delivery to target organs in vivo.

177 Because the liver is one of the primary target organs in VL, unraveling the mechanisms governing

178 ding the ability to accurately visualize the target organ, in particular during laparoscopic surgery.

179 Enhanced TGF-beta in target organs, in turn, can lead to dysregulated tissue

180 ic mucosa invade and metastasize to specific target organs including the intestinal lymph nodes, live

181 rgan can activate protective pathways in the target organ, including the heart and brain.

182 by decreases in numbers of effector cells in target organs, including mast cells, basophils, eosinoph

183 , excess dietary sodium can adversely affect target organs, including the blood vessels, heart, kidne

184 egulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung.

185 f remote ischemic preconditioning in various target organs, including the kidneys.

186 tissue-protective effects of rIPC in various target organs, including the kidneys.

187 that immune cells become activated and enter target organs, including the vasculature and the kidney,

188 t cGVHD manifestations in a wide spectrum of target organs, including those with mucosal surfaces.

189 ese findings suggest that controlling remote target organ inflammation (eg, in the skin) may improve

190 Last, modulation of target organ inflammation (eg, skin) was associated with

191 ion and role of systemic IL-22 in modulating target organ inflammation.

192 With prolonged obesity and development of target organ injury, especially renal injury, obesity-as

193 hich is often mild before the development of target organ injury.

194 g the entry of autoreactive T cells to their target organ is important in autoimmunity because this e

195 An important target organ is the brain, but even though their effects

196 nd to vascular surfaces and extravasate into target organs is an underappreciated, yet essential step

197 Efficient delivery of cells to target organs is critical to improving their effectivene

198 selective inducers of autophagy function in target organs is expected to maximize clinical benefits

199 rafficking of immature DC from blood to GVHD target organs is likely to be regulated by chemokine rec

200 prolonged ischemia/reperfusion injury of the target organ, is an adaptational response that protects

201 he absence of immune cell infiltrates in the target organ (islets and the brain tissue).

202 ectively control autoimmune reactions in the target organ, it may also be necessary to control tissue

203 cells producing IFN-gamma and IL-17 in GVHD target organs, leading to reduction of GVHD and improved

204 a noninvasive method to visualize T1D at the target organ level in patients with active insulitis.

205 ress potential bioactivity at intestinal and target organs level.

206 We show at cellular and target organ levels that network connectivity and functi

207 Whether target organs liberate chemokines to recruit these fibro

208 Host-type dendritic cells from the GVHD target organs liver and spleen or skin- and gut-draining

209 tion showed that neutrophil migration in the target organ lung was significantly reduced in the prese

210 Lupus nephritis is the most common target-organ manifestation and requires individualized c

211 3, hearing loss segregates without any other target-organ manifestations of CAPS.

212 We report that, in the absence of distal target organs, molecular guidance cues can mediate the g

213 of the gastrointestinal (GI) tract, the GVHD target organ most associated with nonrelapse mortality (

214 ntestinal tract (LGI) and liver are the GVHD target organs most associated with treatment failure and

215 tiffness, the impact of aortic stiffening on target organs, noninvasive methods for the measurement o

216 ied the heart as an unexpected but potential target organ of Bmpr2 mutations.

217 We demonstrate that the BM is a major target organ of GVHD in an informative clinically releva

218 rophages accumulated in the kidney, the main target organ of infection, and formed direct contacts wi

219 ntering large amounts of self-antigen in the target organ of the autoimmune disease.

220 ify global transcriptomic differences in the target organ of the virus between chicken lines that dif

221 Although the fetal lung is a major target organ of the virus, HCMV lung pathogenesis has re

222 lls in blood, secondary lymphoid organs, and target organs of aGvHD after BMT showed significantly re

223 scriptional map of immune activation in DENV target organs of an immunocompetent host and supports th

224 dly accumulated in the liver and spleen, the target organs of intracellular infection.

225 dence suggests that the kidneys are not only target organs of many diseases but also can strikingly a

226 hin the peripheral lymphoid compartments and target organs of mice with experimental autoimmune encep

227 Na/K-ATPase was significantly reduced in the target organs of Niemann-Pick type C mice where the intr

228 The target organs of pups in the vaccine group were negative

229 carried the pups to term, and viral loads in target organs of pups were analyzed.

230 me to WNV-infected cells and infiltrate into target organs of Tlr7(-/-) mice.

231 ng in vivo achievable drug concentrations in targeted organs of animal models and subsequent target e

232 and nontarget tissues alike, rather than in target organs only.

233 elies on the recruitment of monocytes to the target organ or tumor and functioning therein as a parac

234 itis without affecting p65 expression in off-target organs or eliciting a humoral response after seri

235 Migration of donor-derived T cells into GVHD target organs plays an essential role in the development

236 sting its potential clinical application for target organ protection in hypertensive cardiovascular d

237 dards should analyze exposure information by target organ, rather than for a single chemical only or

238 o survive, upregulates adhesion molecules in target organs, recruits immune cells capable of entrappi

239 One reason for the impaired target organ reinnervation is degradation of motor endpl

240 mary afferent sensory neurons that innervate target organs release inflammatory neuropeptides in the

241 VDR, has broadened at least 9-fold from the target organs required for calcium homeostasis (intestin

242 The SUVmax and SUVmean of healthy target organs, residual primary tumor, and up to 5 lesio

243 EPCR interaction reduced infiltration in the target organ, resulting in impaired prometastatic activi

244 pansion, activation, and migration into GVHD target organs, resulting in effective prevention of GVHD

245 which expand in the periphery and infiltrate target organs, resulting in tissue damage.

246 drugs in a minimally invasive manner to the target organ(s).

247 anterior pituitary hormones, whereas altered target-organ sensitivity and hormone metabolism result i

248 differences in chemokine expression within a target organ shape the spatial pattern and composition o

249 eneic transplantation mainly in GVHD typical target organs skin, liver, and intestines, whereas no an

250 clinical symptoms in one or more of the main target organs (skin, liver, gastrointestinal tract) and

251 sets in the activation, effector phases, and target organ specificity of acute GVHD.

252 ly that analysis of a more readily evaluable target organ such as skin might shed light on mechanisms

253 sition and inflammatory cell infiltration in target organs such as kidneys and brain lead to complica

254 g through its cognate receptor in peripheral target organs such as liver, muscle, and adipose tissue

255 local autocrine and paracrine factors within target organs such as the heart modulate AMPK is unknown

256 ause T-cell activation and infiltration into target organs such as the vessel and the kidney, which p

257 The anatomical location of various target organs, such as brain, pancreas, and prostate, ma

258 vo and fail to productively infect important target organs, such as the heart or pancreas.

259 r alloreactive T cells trafficking into GVHD target organs, such as the intestines and skin.

260 rnociception, transient viral replication in target organs, systemic production of inflammatory cytok

261 emination of human cytomegalovirus (HCMV) to target organ systems.

262 on windows of susceptibility for particular target organ systems.

263 ring particular windows of susceptibility in target organ systems.

264 quired for entry of cells into inflamed GVHD target organs that lack expression of NKG2D ligands reco

265 ulsatile energy into the microvasculature of target organs that operate at low vascular resistance, a

266 tuberculosis during infection of the primary target organ, that is, the lungs of susceptible individu

267 n controlling herpesvirus replication in the target organ, the lung, and does so by evoking a strong

268 expressed during Mtb infection in the major target organ, the lung, and must be capable of eliciting

269 kedly augment damage in a prototypical cGVHD target organ, the salivary gland.

270 of the active molecules actually reaches the target organ, the skin.

271 nical studies it showed high exposure at the target organ: the skin.

272 at efficiently infiltrate the tumor-burdened target organ; therapeutic efficacy; heightened ratios of

273 In graft-versus-host disease (GVHD) target organs, three recipient CD11b(+) cell subsets (Gr

274 of vaccines based on synthetic materials to target organs, tissues, cells or intracellular compartme

275 i-inflammatory cytokines such as TGF-beta in target organs to counter inflammation.

276 y interrogating transcriptional responses of target organs to MSC therapy.

277 dogs for up to 3 months with no significant target-organ toxicities observed.

278 chniques to evaluate candidate biomarkers of target organ toxicity and to expedite the development of

279 duced sox9b expression levels and subsequent target organ toxicity are unknown.

280 e blood-brain barrier (BBB) and decrease off-target organ toxicity, bevacizumab-loaded poly(D,L-lacti

281 aP exposure leads to dramatic differences in target-organ toxicity and tumor type as a function of do

282 killer (NK) cells, reducing the risk of off-target-organ toxicity.

283 he disseminated tumor cells recruited to the target organs undergo mesenchymal-to-epithelial transiti

284 ional response to infection in multiple DENV target organs using a mouse model of disease.

285 nate from the initial infection focus to the target organs usually through the blood vasculature.

286 Biopsy of target organs (usually skin, skeletal muscles or kidneys

287 educed CMV transmission, with 23.5% infected target organs versus 75.9% in the control group.

288 )F radioactivity in volumes of interest over target organs were determined directly from the PET imag

289 Absorbed dose estimates for all target organs were determined using MIRD schema with OLI

290 cell numbers and homing in lymphoid and GVHD target organs were not considerably affected in MDSC-tre

291 Target organs were related to routes of metabolism and e

292 eactive T cells can become pathogenic in the target organ where high concentrations of antigen and/or

293 The gill was the main target organ where immature and mature poxvirus particle

294 settings, intestinal Th17 cells migrate into target organs, where they contribute to pathology.

295 o inhibit T-effector cell trafficking to the target organ, while antigen-specific iTregs primarily pr

296 tly combining an endogenous peptide from the target organ with a synthetic small molecule inhibitor i

297 e heart was identified as the most sensitive target organ with rapid onset of extensive platelet aggr

298 ATAK cells accumulated in target organs with distinct profiles, depending on the m

299 Vegf induced differential gene expression in target organs, with Il10 and Mmp8 displaying consistent

300 hich achieve high drug concentrations in the target organ, would more effectively treat respiratory i